# Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )

> **NCT07720921** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Neoadjuvant Therapy

## Interventions

- **RADIATION:** Neoadjuvant radiotherapy
- **DRUG:** ADC + PD1 monoclonal antibody

## Key facts

- **NCT ID:** NCT07720921
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720921, "Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*